Background: Primary aldosteronism (PA) may confer increased cardiovascular risk
| INTRODUC TI ON
Primary aldosteronism (PA), due to autonomous adrenal aldosterone secretion, is considered to be a rather frequent cause of endocrine hypertension. 1, 2 During the past few years, evidence is accumulating that the risk of cardiovascular morbidity and mortality is increased in PA patients compared to patients with essential hypertension even when taking account of the systemic blood pressure level. 5, 6 In line,
a recent meta-analysis demonstrated a greater carotid artery intima media thickness, a marker of subclinical atherosclerosis, in PA patients compared to individuals with essential hypertension.
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Besides key roles in regulating electrolyte and fluid balance, aldosterone has been identified to exert pro-inflammatory and profibrotic effects on arterial tissue and the heart, and to enhance circulating levels of pro-inflammatory cytokines. 10, 11 Moreover, PA may be associated with a higher prevalence of the metabolic syndrome (MetS). 15, 16 Elevated fasting glucose levels have been equivocally reported in PA, 6, 7, 17, 18 whereas several population-based studies have suggested an association of higher plasma aldosterone with increased prevalence of MetS or insulin resistance. 19, 20 Some reports have pointed to an association of high circulating aldosterone concentrations with decreased levels of high-density lipoprotein cholesterol (HDL-C). 13, 15, 19 Remarkably however, plasma total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG) were documented to be lower in PA patients compared to subjects with essential hypertension and normotensive control subjects, 6, 8 although unchanged levels of TC, LDL-C and TG in PA have been found in other studies. 7, 18, 20, 21 Additionally, HDL-C was found to decrease, whereas triglycerides were increased after unilateral adrenalectomy or mineralocorticoid receptor antagonist treatment in PA. 22 Notably, circulating high sensitivity C-reactive protein (hsCRP) levels reflecting low-grade systemic inflammation have been variably shown to be unchanged or elevated in PA patients, possibly coinciding with increased oxidative stress. 13, 21, 23 Despite ongoing interest in pro-atherogenic alterations in metabolic and inflammatory processes conveyed by PA, little is currently known about the relationship of PA with possible alterations in lipoprotein particle characteristics. In this regard, it is relevant that measurement of lipoprotein particle concentrations by nuclear magnetic resonance (NMR) spectroscopy may provide additional insight into the prediction of cardiovascular disease beyond conventional lipid measures. 24, 25 Of further note, using the same NMR spectroscopy-based technique, an assay, designated GlycA, has been developed, which represents a composite marker of five abundant inflammatory glycoproteins. 26, 27 GlycA is strongly correlated with hsCRP, and has the advantage of being less variable within individual subjects compared to hsCRP. 26, 27 GlycA has been shown to be elevated in MetS, 29, 30 and predicts newly developed type 2 diabetes mellitus (T2DM), 31 as well as cardiovascular disease. 32 The same NMR spectroscopy-based technique enables measurement of plasma concentrations of total branched-chain amino acids (BCAA), that is valine, leucine and isoleucine, which may be implicated in the pathogenesis of insulin resistance and other pathologies. 33, 34 We initiated the present study to determine the extent to which (apo)lipoproteins, lipoprotein particle concentrations, GlycA and BCAA, as determined by NMR spectroscopy, were altered in individuals with PA, compared to non-hypertensive control subjects, subjects with untreated hypertension and subjects with medically treated hypertension. The latter three groups of subjects were participants in the Prevention of Renal and Vascular End-stage Disease (PREVEND) cohort study, representing a Dutch cohort recruited from the general population of the city of Groningen, the Netherlands.
| SUBJEC TS AND ME THODS

| Participants
All studies were performed in the University Medical Center Groningen, the Netherlands.
The PA group consisted of 23 subjects with biochemically confirmed PA, that is elevated plasma aldosterone-renin ratio and non- In order to compare data from the PA group with appropriate comparator groups, three groups of participants in the PREVEND study were selected: (a) control subjects without hypertension; (b) subjects with untreated hypertension; and (c) subjects with treated hypertension. The latter group was included to take account of potential confounding due to antihypertensive treatment. The PREVEND study investigates vascular and renal damage among inhabitants of the city of Groningen, the Netherlands, in a predominantly white population. Details of the study have been described elsewhere. 28, 31, 32, 37 In short, after exclusion of subjects with insulin-treated diabetes and pregnant women, all subjects with a urinary albumin concentration ≥10 mg/L were invited to participate (n = 7768), of whom 6000 accepted. In addition, a random Characteristics of the PA group and the three comparator groups from the PREVEND cohort are presented in Table 1 . In total, the 20 PA patients were matched with 2819 control subjects without hypertension, 501 untreated hypertensive subjects and 878 subjects with treated hypertension.
| Procedures and data ascertainment
Body mass index was calculated as weight (in kg) divided by height squared (in metre). Smoking status was categorized as current (yes/no). In the PA subjects with PA, blood pressure was on the right arm in the supine position using a sphygmomanometer during routine patient care. In PREVEND participants, Data are given in means ± SD or in numbers. ARR, aldosterone-renin ratio; BMI, body mass index; eGFR, estimated glomerular filtration rate; PRC, plasma renin concentration; SLT, salt loading test. P-values compared to the primary aldosteronism group: *P < 0.016; **P < 0.01; ***P < 0.001. P-values <0.016 are considered significant.
plasma glucose level >7.0 mmol/L, a non-fasting plasma glucose level >11.1 mmol/L, self-report of a physician diagnosis and/or the use of glucose lowering drugs, retrieved from a central pharmacy registry. Information on self-reported medication was combined with information from a pharmacy-dispensing registry, which has complete information on drug usage/consumption of >95% of subjects participating in PREVEND. 28, 31, 32 All participants were instructed to let venous blood being drawn after an overnight fast. Blood samples were taken after 15 minutes rest.
| Laboratory methods
Ethylenediaminetetraacetic acid (EDTA) anti-coagulated venous blood samples were prepared by centrifugation at 1400 × g for 15 minutes and stored at −80°C until assay. Plasma samples were sent frozen to LabCorp, Morrisville, NC, USA, for testing.
Nuclear magnetic resonance spectra were acquired on a Vantera ® Clinical Analyzer from EDTA plasma samples as previously described for the NMR LipoProfile ® test at LabCorp (Morrisville, NC, USA).
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The NMR MetaboProfile analysis, which reports lipoprotein particle concentrations and sizes, as well as concentrations total BCAA, that is the sum of valine, leucine, and isoleucine, was performed using the recently developed LP4 lipoprotein profile deconvolution algorithm.
Linear regression of the lipoprotein subclass signal areas against serum lipid and apolipoprotein levels measured chemically in a large reference range study population (n = 698) provided the conversion factors to generate NMR-derived concentrations of TC, TG, LDL-C and HDL-C, apolipoprotein B (apoB) and apolipoprotein A-I (apoA-I).
The inter-assay precision for these parameters ranges from 1.4% to 6.2%. NMR-derived concentrations of these parameters are highly correlated (r ≥ 0.95) with those measured by standard methods.
The diameters and inter-assay precision (% coefficients of variation [CV]) for the lipoprotein classes reported by the LP4 algorithm are triglyceride-rich lipoprotein particles (TRL-P; 24-240 nm; 6.4%), LDL particles (LDL-P; 19-23 nm; 1.5%) and HDL particles (HDL-P;
7.4-12.0 nm; 2.4%). Of note, LDL-P and HDL-P generated from the LP4 algorithm have been calibrated to be closer to the absolute concentrations of LDL and HDL particles. Consequently, the LDL and HDL particle concentrations are expected to be on average higher and lower, respectively, than those reported by the previous LP2 and LP3 algorithms. Mean TRL, LDL and HDL particle sizes are weighted averages derived from the sum of the diameter of each subclass multiplied by its relative mass percentage.
The GlycA signal was quantified as previously described. was used for data analysis. Data are given in means ± SD, medians (interquartile ranges) or in numbers (percentages). The difference in various variables in the PA group compared to the matched control subjects without hypertension, subjects with untreated hypertension and subjects with treated hypertension was expressed as differences in SD-scores (Z-scores). Since we performed three independent comparisons, the threshold for statistical significance was, therefore, set at two-sided P-values <0.05/3 = <0.016. Table 2 shows plasma lipids and (apo)lipoproteins, lipoprotein particle concentrations and sizes, GlycA and BCAA in the PA group (n = 20)
| RE SULTS
in comparison with three groups of unmatched control subjects without hypertension (n = 3876), subjects with untreated hypertension (n = 644) and subjects with treated hypertension (n = 944). Plasma TC and LDL-C were lower in the PA group compared to the three comparator groups. In line with lower LDL-C, also LDL-P and apoB were lower in the PA group compared to all comparator groups. HDL-C was lower in the PA group compared to the normotensive and untreated hypertensive control groups as was apoA-I. HDL-P was lower in the PA group compared to all control groups. Lipoprotein particle sizes
were not different between the groups. GlycA was higher in the PA group compared to the control group of subjects without hypertension. The total BCAA concentration was not different in the PA group compared to the three comparator groups, although leucine was lower in PA vs (untreated) hypertension. Table 3 demonstrates the comparison between the PA group and three matched groups of control subjects without hypertension (n = 2819), subjects with untreated hypertension (n = 501) and subjects with treated hypertension (n = 878). Plasma TC and LDL-C were lower in the PA group vs the three comparator groups. HDL-C was also decreased in the PA group, although the difference with the group of subjects with treated hypertension did not reach significance. In line with lower LDL-C and HDL-C, respectively, apoB and apoA-I were also lower in the PA group. Consistent with lower LDL-C and apoB, LDL-P was decreased in the PA group. Furthermore, consistent with lower HDL-C and apoA-I, HDL-P was decreased in the PA group as well.
However, neither LDL nor HDL size was altered in PA patients. Plasma TG concentrations were lower in the PA group vs the group of subjects with untreated hypertension, whereas TRL-P was decreased in PA vs subjects with untreated and treated hypertension. TRL size was also decreased in PA subjects vs subjects with treated hypertension.
GlycA was increased in the PA group vs the three comparator groups (Table 4) . Plasma total BCAA were not different in the PA group vs the three comparator groups, although PA patients showed an increase in isoleucine vs the subjects with treated hypertension, whereas leucine was lower in PA patients vs control subjects without hypertension and subjects with untreated hypertension (Table 4) .
| D ISCUSS I ON
The present study is the first to compare a comprehensive set of (apo)lipoproteins, lipoprotein particle characteristics and other metabolic variables between PA patients, normotensive control subjects and subjects with treated and untreated hypertension, using novel NMR spectroscopy-based methodology. The application of such techniques enables measurement of lipoprotein particle concentrations, as well as GlycA, a pro-inflammatory glycoprotein biomarker, and BCAA obtained from the same NMR spectra without the need to suppress protein and other signals. 26, 34, 38, 39, 42 Previous studies on conventional circulating lipoprotein levels have variably reported lower or unchanged levels of plasma TC, LDL-C and TG, in addition to decreased or unaltered HDL-C in PA compared to healthy subjects or subjects with essential hypertension. 6, 8, 18, 20, 21 In one of these studies, lower TC, LDL-C and TG levels in PA patients compared to normotensive and hypertensive control subjects were suggested to be in part attributable to measurement of lipoproteins in the non-fasting state of the control subjects included. 3 Here, we show that plasma TC, LDL-C, HDL-C, apoB, apoA-I, LDL particle and HDL particle concentrations in the fasting state are all decreased in PA vs control subjects and subjects with untreated hypertension, with most of these (apo)
lipoprotein variables also being decreased compared to subjects with treated hypertension. In addition, plasma TG and TRL particle concentrations were decreased in PA compared to several comparator groups. The decrements in LDL and HDL particle concentrations did not result in changes in the mean particle diame- Data are given in mean ± SD. apo, apolipoprotein; BCAA, branched-chain amino acids; HDL, high-density lipoprotein; HDL-C, HDL cholesterol; HDL-P, HDL particles; LDL low-density lipoproteins, LDL-C, LDL cholesterol; LDL-P, LDL particles; TRL, triglyceride-rich lipoproteins, TRL-P, TRL particles. P-values compared to the primary aldosteronism group: *P < 0.016; **P < 0.01; ***P < 0.001. P-values <0.016 are considered significant.
may contribute adrenal steroidogenesis, but it seems unlikely that increased adrenal aldosterone production in PA would result in lower LDL and HDL particle concentrations. 35 Liver X receptors (LXR) are known to be influenced by the renin-angiotensin-aldosterone system, but it is unclear whether high aldosterone, or suppressed renin as its consequence, may directly affect lipoprotein metabolism via LXR regulation.
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Decreased LDL, HDL and to some extent also TRL particle concentrations are unexpected in the light of a possible increased prevalence of MetS and impaired insulin sensitivity in PA. 16, 17, 44 In comparison, plasma TG levels are elevated in subjects with endogenous glucocorticoid excess, which results in lower hepatic lipase activity in post-heparin plasma as well in downregulation of cholesteryl ester transfer protein, thereby at least in part maintaining HDL-C. 45, 46 Taken together, the present study suggests that PA is characterized by a remarkable, if not unique, lipoprotein profile that consists of decreases in both LDL and HDL particles without affecting TRL.
The GlycA signal originates from methyl groups of N-acetylglucosamine (GlcNAc) containing carbohydrate side-chains of several abundant glycoproteins, and GlycA measures the glycan content of proteins, not the protein concentrations as such. 26, 27 Only the GlcNAc moieties in β(1 → 2) or β(1 → 6) linkage with a preceding mannose give rise to the GlycA NMR signal. 26 During the past few years, evidence has accumulated that GlycA associates with insulin resistance and MetS, predicts the development of new onset T2DM even when taking account of hsCRP levels and relates to the cardiovascular risk marker, lipoprotein-associated phospholipase A2. 27, [29] [30] [31] [46] [47] [48] GlycA has been shown to predict the atherosclerotic cardiovascular disease in population-based cohorts and in high-risk TA B L E 3 Differences in plasma lipids and (apo)lipoproteins, lipoprotein particle concentrations and sizes in primary aldosteronism patients compared to matched normotensive control subjects, subjects with untreated hypertension and subjects with treated hypertension Differences of the primary aldosteronism group with three control groups are given as standard deviation scores (Z-scores) with corresponding 95% confidence intervals. apo, apolipoprotein; HDL, high-density lipoprotein; HDL-C, HDL cholesterol; HDL-P, HDL particles; LDL, low-density lipoproteins, LDL-C, LDL cholesterol; LDL-P, LDL particles; TRL, triglyceride-rich lipoproteins, TRL-P, TRL particles.
P-values compared to the primary aldosteronism group: *P < 0.05; **P < 0.016; ***P < 0.01 ****P < 0.001 are considered significant.
TA B L E 4
GlycA, branched-chain amino acids (BCAA), valine, isoleucine and leucine in primary aldosteronism patients compared with matched normotensive control subjects, subjects with untreated hypertension and subjects with treated hypertension Differences of the primary aldosteronism group with three control groups are given as standard deviation scores (Z-scores) with corresponding 95% confidence intervals.
*P < 0.05; **P < 0.016; ***P < 0.01; ****P < 0.001 are considered significant.
patient groups, even independent of eGFR and urinary albumin excretion. 32, [49] [50] [51] GlycA also predicts hospitalization for heart failure. 51 Of further relevance, one of the acute phase proteins captured in the GlycA signal, alpha-1-acid glycoprotein, has been identified as a marker of all-cause mortality in the general population. 51 In the PREVEND cohort, high GlycA levels were associated with reduced life expectancy (Gruppen et al this paper). Collectively, the present findings showing an increase in GlycA in PA consents with the notion that this condition gives rise to a state of low grade enhanced systemic inflammation. 13, 16 Hence, it is plausible to postulate that low-grade systemic inflammation could contribute to the negative impact of PA on (cardiovascular) morbidity. 6, 7 The BCAA, valine, leucine and isoleucine, are essential amino acids that not only regulate protein production and catabolism but are also involved in glucose metabolism. 33, 34, 40, 52, 53 BCAA may be implicated in the development of insulin resistance by enhancing mitochondrial stress. On the other hand, insulin resistance itself could elicit higher fasting BCAA levels. 54 Using the same NMR-based technique, we recently reported elevated BCAA levels in T2DM
and MetS, and observed a positive association of carotid intima media thickness with BCAA. 35 In the present study, no alterations in plasma total BCCA were observed in PA vs the various comparator populations. This makes an important contribution of abnormalities in BCAA metabolism on possible cardiometabolic abnormalities in PA unlikely.
The present study has strengths and limitations. We excluded three PA patients with T2DM. Consequently, we also excluded PREVEND subjects with T2DM. Additionally, PREVEND participants with compromised kidney function were excluded. These exclusion criteria were applied in order to circumvent bias due to diabetes-and chronic kidney disease-associated alterations in lipoprotein variables, GlycA and BCAA in the various comparator groups. Furthermore, although the PA group studied was moderately sized, these patients were individually matched with a considerable number of PREVEND participants. This approach was chosen to increase statistical power in comparing lipoprotein variables, GlycA and BCAA levels in PA patients with control subjects without hypertension and subjects with (treated) hypertension.
However, it should be appreciated that we did not aim to compare the presently studied NMR-based variables between these three comparator groups. In view of the set-up of the present report, fasting plasma glucose and insulin levels were not available in PA patients, obviating the ability to demonstrate differences in insulin resistance and β-cell function between PA patients and the various comparator groups. Additionally, co-secretion of cortisol was not formally excluded in PA patients. Theoretically, cortisol cosecretion could have influenced lipoprotein profiles. Most likely, however, co-secretion of cortisol would have resulted in increased levels of LDL cholesterol and triglycerides, contrasting with our findings of significantly lower levels of LDL particle concentration and LDL-C as well as a tendency towards lower levels of triglycerides. 55, 56 It should also be noted that the PA patients were of north European descent as were far most PREVEND participants.
The present findings, therefore, do not necessarily hold true for non-white ethnicities. Finally, the moderate number of PA patients included in this report did not allow to provide meaningful analysis regarding possible differences in NMR-based variables between patients with a unilateral aldosterone producing adenoma and patients with bilateral adrenal hyperplasia. 57 In conclusion, the present report demonstrates that PA is associated with decreases in plasma total cholesterol, LDL cholesterol, HDL cholesterol, apolipoprotein B and A-I, as well as in LDL and HDL particle concentrations and to some extent also with lower TG and TRL particle concentrations. This suggests that PA is featured by a rather unique lipoprotein profile. Furthermore, PA is characterized by increased GlycA levels, indicating enhanced lowgrade chronic inflammation. Low HDL particle concentrations and increased GlycA could contribute to accelerated development of atherosclerotic cardiovascular disease in PA.
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